News ArchivesRead News

New Gene Therapy Shown to Help Parkinson's Disease

Wednesday March 23, 2011

Media Newswire - An Ohio State researcher says treatment using a novel gene therapy agent has proven to significantly improve motor skills in patients with advanced Parkinson’s disease.

The study, published online today ( 3/16 ) in the journal Lancet Neurology, is the first randomized, double blind study to provide definitive clinical proof that gene therapy works in the human brain.

“This is passing a threshold never achieved before in gene therapy,” says Dr. Matthew J. During, researcher at The Ohio State University Medical Center, and co-developer of the gene therapy treatment.

Patients involved in the study received either a placebo infusion of sterile saline, or the study therapy, which is the glutamic acid decarboxylase ( GAD ) gene delivered within a protein shell. GAD makes a neurochemical called GABA that helps restore chemical balance in areas of the brain where Parkinson’s disease causes abnormal levels of activity. The infusion went into the key parts of the brain that are responsible for motor function.

Prior to the procedure, the patients’ motor skills were evaluated, using scores from an overnight, off-medication rating scale. Researchers compared these baseline scores to the progress of the same patients at intervals at one, three and six months after the procedure. The results were significant. At the end of six months, among those receiving the gene therapy, half improved by nine points or more, compared to just 14 percent of those receiving the placebo.

“That translates into moderate to large clinical improvement. Patients reported more consistent medication effect and noticeable improvements in symptoms such as tremors, rigidity, slowness of movement and slowness of gait,” says During, a professor of molecular virology, immunology and medical genetics, neuroscience and neurological surgery at Ohio State University College of Medicine.

Approximately one million people live with Parkinson’s disease in the United States, and up to six million are affected worldwide. As the disease progresses, it becomes more difficult to control the symptoms with medication and patients often develop significant side effects. Another treatment option, deep brain stimulation, involves implanting medical devices permanently in the brain.

The randomized, controlled double blind clinical trial enrolled 45 patients with moderate to advanced Parkinson’s disease at seven sites in the United States, including Ohio State’s Medical Center, between November 2008 and May 2010.

The gene therapy was developed by During and Dr. Michael Kaplitt at New York-Presbyterian Hospital/Weill Cornell Medical Center, the co-founders of Neurologix, Inc. The phase II trial was sponsored by Neurologix, Inc., Fort Lee, N.J. where During is a paid consultant.

Other Ohio State researchers involved in the study are Dr. Sandra Kostyk, Dr. Ali Rezai and Dr. Punit Agrawal.

Researchers are already planning for the phase III trial of this gene therapy. During and his colleagues are meeting with the U.S. Food and Drug Administration to develop the testing sites and protocol for the next round of research.

“Our work here at Ohio State has been instrumental in the development of this novel therapy and we obviously want to be a phase III study site as well,” During said.

Recent News

Nov 22 - A caregiver's story: Living and loving through the slow process of dying
Nov 19 - Testosterone cause of sex differences in the occurrence of Parkinson’s disease, new research suggests
Nov 18 - New strategy reduces side effects in Parkinson's treatment
Nov 14 - Opinion: The never-ending tests of Parkinson's disease
Nov 13 - Parkinson’s disease: A new tool for diagnosis
Nov 10 - Parkinson's Disease Drug May Be Useful For Delaying, Preventing Blindness In Older Population
Nov 9 - Microsoft VP’s diagnosis fuels employees’ heartfelt efforts to help others
Nov 6 - Lewy body dementia: unrecognized and misdiagnosed
Nov 5 - Gait difficulties in Parkinson's linked to new blood vessels in brain
Oct 30 - Special Section: Enabling Technologies for Parkinson’s Disease Management
Oct 27 - Scientists discover a 'switchboard' of molecules that protect against Parkinson's disease
Oct 26 - Dancing improves mobility and quality of life in people with Parkinson's
Oct 23 - The amazing woman who can smell Parkinson’s disease — before symptoms appear
Oct 20 - Personal Essay: The deviousness of dementia
Oct 19 - Mechanism that 'melts' protein clumps may lead to new Parkinson's treatments
Oct 19 - Researchers find that stem cell treatment may reduce cognitive impairment related to dementia with Lewy bodies
Oct 17 - Cancer Drug Helps Parkinson's Patients
Oct 12 - Researchers identify immune gene that can prevent Parkinson's disease and dementia
Oct 12 - Blog Post: An Alert, Well-Hydrated Artist in No Acute Distress
Oct 7 - This month, a brain surgery will be broadcast on live TV for the first time ever